Prexton Therapeutics

Prexton has the objective to develop novel small molecules on mGluR4 as new treatment for Parkinson’s disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Champel, Geneva, GE, Switzerland
  • Currency USD
  • Founded July 2012
  • Employees 4
  • Website prextontherapeutics.com

Company Summary

Prexton is biotech founded as a spin off of Merck Serono, with assets primarily developed at Merck Serono. The objective is to develop small molecules for Parkinson's disease. The target is mGluR4, which has been recently validated in animal models of Parkinson's. All employees of Prexton are formerly Merck Serono's employees. Preclinical and clinical development is outsourced.

Team

  • François Conquet
    CEO

    Director L&BD Merck Serono (2006-2012). - Founder and CEO of Addex Pharmaceuticals (ADXN-Zurich) (2001-2004) - Acting CEO for 3 French Biotechs (2004-2006)
    Dept Head GSK R&D (1991-2001) and author of 40 articles on mGluRs (2 Nature)

  • François Conquet

Advisors

  • Maître Jacques Bonvin, Tavernier & Tschanz, Geneva
    Lawyer
    Unconfirmed
    Olivier Bétrisey, GVA-Audit, Geneva
    Accountant
    Unconfirmed

Previous Investors

  • Merck Serono Ventures
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free